Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib

A large number of EGFR mutant non‐small cell lung cancer patients primordially benefit from first‐line treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. However, multiple acquired resistance mechanisms have been described that limit the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Kejing, Jiang, Neng, Kuang, Yukun, He, Qiong, Li, Shuhua, Luo, Jiping, Jiang, Wenting, Chen, Yangshan, Sun, Yu, Chen, Lili, Chen, Yanyang, Zhu, Junfeng, Cui, Yongmei, Wan, Han, Ke, Zunfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360229/
https://www.ncbi.nlm.nih.gov/pubmed/30521113
http://dx.doi.org/10.1111/1759-7714.12927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360229/
https://www.ncbi.nlm.nih.gov/pubmed/30521113
http://dx.doi.org/10.1111/1759-7714.12927

Ejemplares similares